Mirador Capital Partners LP Grows Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Mirador Capital Partners LP raised its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,825 shares of the company’s stock after purchasing an additional 940 shares during the quarter. Mirador Capital Partners LP’s holdings in 10x Genomics were worth $1,082,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in 10x Genomics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 9,011,332 shares of the company’s stock worth $504,274,000 after acquiring an additional 107,815 shares in the last quarter. ARK Investment Management LLC increased its holdings in 10x Genomics by 35.0% during the fourth quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock valued at $226,150,000 after buying an additional 1,047,827 shares during the period. Brown Capital Management LLC raised its stake in 10x Genomics by 14.5% in the fourth quarter. Brown Capital Management LLC now owns 3,527,297 shares of the company’s stock worth $197,388,000 after buying an additional 446,192 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in 10x Genomics by 32.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock worth $127,786,000 after buying an additional 565,059 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its holdings in 10x Genomics by 32.9% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 2,283,530 shares of the company’s stock worth $127,764,000 after buying an additional 565,059 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,087 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the transaction, the insider now directly owns 350,055 shares of the company’s stock, valued at $8,506,336.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Serge Saxonov sold 4,877 shares of 10x Genomics stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $118,511.10. Following the completion of the transaction, the chief executive officer now owns 889,641 shares in the company, valued at approximately $21,618,276.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,087 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $99,314.10. Following the transaction, the insider now owns 350,055 shares in the company, valued at approximately $8,506,336.50. The disclosure for this sale can be found here. Insiders have sold a total of 11,900 shares of company stock valued at $289,170 over the last ninety days. Company insiders own 10.03% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wolfe Research reissued a “peer perform” rating on shares of 10x Genomics in a research report on Thursday. Deutsche Bank Aktiengesellschaft reduced their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, April 18th. UBS Group cut their price objective on shares of 10x Genomics from $52.00 to $30.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. Canaccord Genuity Group decreased their target price on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 29th. Finally, Barclays cut their price target on shares of 10x Genomics from $36.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $45.00.

10x Genomics Stock Performance

TXG traded up $0.04 during trading on Monday, reaching $19.49. 119,662 shares of the company’s stock were exchanged, compared to its average volume of 1,515,866. The company’s fifty day simple moving average is $23.62 and its 200-day simple moving average is $36.84. 10x Genomics, Inc. has a 1 year low of $18.39 and a 1 year high of $63.57.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). The company had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.44) earnings per share. On average, analysts anticipate that 10x Genomics, Inc. will post -1.53 EPS for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.